IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Windlas Biotech IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 401.54 Cr. The company is based in Dehradun and caters to Pharmaceutical sector. Dam Capital Advisors (Formerly Idfc Securities ) , IIFL Securities , SBI Capital Markets are the merchant bankers of Windlas Biotech IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 13th May 2021.
Windlas Biotech IPO posted revenues of ₹ 430.70 crores and PAT of ₹ 15.57 crores in FY25 on annualised basis.
Revenue:
₹ 427.60 Cr.
EBITDA Margin:
8.42
% 
Net Worth: ₹ 199.12 Cr.
Market Capitalisation:
[●]
P/E:
64.00 times
P/BV: [●]
EV/EBITDA: 0.40 times
Financial results of Windlas Biotech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY21 | FY20 | FY19 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 296.12 | 338.49 | 298.18 | ||
| Net Worth | 199.12 | 209.66 | 193.59 | ||
| Total Debt | 30.24 | 22.16 | 22.90 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
427.60 | 328.85 | 307.27 | ||
EBITDA
EBITDA on annualised basis |
36.00 | 36.49 | 91.54 | ||
PAT
PAT on annualised basis |
15.57 | 16.21 | 63.82 | ||
Windlas Biotech IPO PAT Margin is 3.64 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Windlas Biotech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY21 | FY20 | FY19 |
|---|---|---|---|
| EBITDA Margin (%) | 8.42 | 11.10 | 29.79 |
| PAT Margin (%) | 3.64 | 4.93 | 20.77 |
| EPS (₹) | 8.70 | 8.90 | 38.61 |
| ROE (%) | 7.82 | 7.73 | 32.97 |
| ROCE (%) | [●] | [●] | [●] |
| ROA (%) | 5.26 | 4.79 | 21.40 |
| Debt to Equity | 0.15 | 0.11 | 0.12 |
The market Capitalisation of Windlas Biotech IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Windlas Biotech IPO prospectus highlights an Return on Equity (ROE) of 7.82 % , Return on Assets (ROA) of 5.26 %, and an EBITDA Margin of 8.42 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Windlas Biotech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Windlas Biotech IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Windlas Biotech IPO has a Price-to-Earnings (PE) ratio of 64.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Windlas Biotech IPO reported revenue of ₹ 430.70 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Windlas Biotech IPO provide insights into sales growth, market demand, and business scalability.
Windlas Biotech recorded an EBITDA of ₹ 36.00 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Windlas Biotech Profit After Tax (PAT) is ₹ 15.57 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 427.60 Cr.
EBITDA Margin:
8.42
%
Net Worth: ₹ 199.12 Cr.
Market Capitalisation:
[●]
P/E:
64.00 times
P/BV: [●]
EV/EBITDA: 0.40 times
Windlas Biotech operates in Pharmaceutical and Domestic Pharmaceutical Formulations Contract Development And Manufacturing. The Issue is listed on BSE,NSE in Aug, 2021. Windlas Biotech IPO size was 401.54 with Issue price of 460.00 .
Merchant Banker(s) of Windlas Biotech IPO: Dam Capital Advisors Limited (Formerly Idfc Securities Limited) , IIFL Securities Limited , SBI Capital Markets Limited
Windlas Biotech IPO subscription was 22.44 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Windlas Biotech IPO listed at a listing price of 406.70 against the offer price of 460.00.
The current market price of Windlas Biotech is 901.25.
Why Us?
